Consistent with the low mutational burden of AML, we found a very low frequency of BCL7A mutations in AML samples (< 1% non-synonymous coding mutations; N = 230; see Methods), ruling out mutations as a mechanism of BCL7A inactivation in AML. The gene discussed is BCL7A; the disease is acute myeloid leukemia.